Vera Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.91 M

Shareholding (Mar 2025)

FII

17.67%

Held by 103 FIIs

DII

35.46%

Held by 41 DIIs

Promoter

12.82%

How big is Vera Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Vera Therapeutics, Inc. has a market capitalization of $1.35 billion, with net sales of $0.00 million and a net profit of -$175.45 million over the latest four quarters. The company reported shareholder's funds of $577.15 million and total assets of $656.47 million as of Dec 24.

What does Vera Therapeutics, Inc. do?

22-Jun-2025

Vera Therapeutics, Inc. is a small-cap biotechnology company focused on pharmaceuticals, currently reporting a net profit loss of $52 million and a market cap of approximately $1.35 billion. The company has no dividend yield and negative return on equity.

Is Vera Therapeutics, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Vera Therapeutics, Inc. shows a bullish trend supported by weekly indicators, despite underperforming the S&P 500 year-to-date and having mixed monthly signals that suggest caution.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,580 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-46.61%

Price to Book

3.37

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-77 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

85.58%

6 Months

37.85%

1 Year

-13.71%

2 Years

207.88%

3 Years

161.41%

4 Years

51.91%

5 Years

0.0%

Vera Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Vera Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Vera Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, supported by a bullish signal from the KST and OBV. The daily moving averages also indicate a bullish stance. However, the monthly MACD and KST are bearish to mildly bearish, which suggests some caution. The Bollinger Bands show a mildly bullish trend on the weekly chart but are mildly bearish on the monthly. Overall, the weekly indicators are stronger, indicating a bullish sentiment. In terms of performance, the stock has underperformed the S&P 500 year-to-date, down 30.91% compared to the S&P's 15.47%, but has shown a significant return of 60.2% over the last three years, although it still lags behind the S&P's 78.85% return in the same period....

Is Vera Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Vera Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, supporting the positive outlook. However, the monthly MACD and KST are bearish or mildly bearish, indicating some caution. The Bollinger Bands show a mildly bullish stance on the weekly timeframe but mildly bearish on the monthly. The Dow Theory indicates a mildly bullish trend in both weekly and monthly perspectives. In terms of performance, the stock has underperformed the S&P 500 year-to-date, down 30.91% compared to the S&P's 15.47%, and over the past year, it is down 26.56% while the S&P has gained 16.90%. Overall, the current technical stance is bullish, but with mixed signals from longer-term indicators suggesting a need for caution....

Is Vera Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Vera Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Additionally, the KST and OBV on a weekly basis are bullish, supporting the overall positive trend. However, the monthly MACD and KST are bearish and mildly bearish, respectively, which suggests some caution. The Bollinger Bands show a mildly bullish signal weekly but a mildly bearish signal monthly, indicating mixed signals across time frames. In terms of performance, the stock has underperformed the S&P 500 year-to-date and over the past year, with returns of -30.91% and -26.56%, respectively, compared to the S&P 500's returns of 15.47% and 16.90%. Despite the current bullish trend, the overall performance relative to the benchmark raises concerns about sustainability....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-313.43%

EBIT to Interest (avg)

-32.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.71

EV to EBIT

-4.71

EV to EBITDA

-4.75

EV to Capital Employed

-332.58

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-32.79%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 55 Schemes (34.06%)

Foreign Institutions

Held by 103 Foreign Institutions (17.67%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -127.00% vs -66.83% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-79.60",
          "val2": "-37.30",
          "chgp": "-113.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-76.50",
          "val2": "-33.70",
          "chgp": "-127.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -58.44% vs -7.74% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-165.00",
          "val2": "-103.90",
          "chgp": "-58.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "3.80",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-152.10",
          "val2": "-96.00",
          "chgp": "-58.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-79.60

-37.30

-113.40%

Interest

1.90

Exceptional Items

0.00

-0.00

Consolidate Net Profit

-76.50

-33.70

-127.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -127.00% vs -66.83% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-165.00

-103.90

-58.81%

Interest

7.60

3.80

100.00%

Exceptional Items

0.00

-0.00

Consolidate Net Profit

-152.10

-96.00

-58.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -58.44% vs -7.74% in Dec 2023

All Annual Results

Company CV

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Vera Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Vera Therapeutics, Inc.?

Watch in Real-Time

What does Vera Therapeutics, Inc. do?

Is Vera Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Vera Therapeutics, Inc. technically bullish or bearish?

Is Vera Therapeutics, Inc. technically bullish or bearish?

Is Vera Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Vera Therapeutics, Inc.

Company Coordinates